{
  "id": 7542701,
  "title": "Arrowhead reports phase 1/2a data for dual-gene RNAi therapy",
  "url": "https://urgent.news/2026/09/15/arrowhead-reports-phase-1-2a-data-for-dual-gene-rnai-therapy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T11:36:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/arrowhead-reports-phase-12a-data-for-dualgene-rnai-therapy-93CH-4901437"
  },
  "original_language": "en",
  "account": "PASADENA, Calif. - Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) disclosed interim topline results from a Phase 1/2a clinical trial of ARO-DIMER-PA, an experimental RNA interference therapy aimed at silencing two genes at once for mixed hyperlipidemia-related atherosclerotic cardiovascular disease. The study showed significant reductions in serum PCSK9 (72% decrease) and APOC3 (88% decrease) in participants with mixed hyperlipidemia. By silencing both genes, ARO-DIMER-PA led to substantial mean reductions in LDL-C (54%), triglycerides (73%), non-HDL cholesterol (61%), and Apolipoprotein B levels. This marks the first clinical validation of targeting and silencing two genes simultaneously with a single RNAi molecule. The single dose escalation reached 400 mg, with the most frequently reported adverse events being injection site issues and headaches. No serious drug-related adverse events were observed. The trial will continue to evaluate the safety and tolerability of various doses. ARO-DIMER-PA is the first in its class to specifically target two genes simultaneously using RNAi technology, addressing the major risk factor for atherosclerotic cardiovascular disease.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}